Celularity Inc. (NASDAQ:CELU) announced it has signed agreements for a strategic commercialization partnership involving its placental-derived biomaterials portfolio, a transaction that could generate up to $35 million through upfront and milestone-based payments.
The deal, expected to close by April 15, 2026, grants an exclusive license to Celularity’s commercial-stage biomaterials products along with certain development-stage programs. The company will receive an upfront payment at closing and may earn additional milestone payments bringing the potential total to $35 million. Celularity will also be entitled to royalties on future net sales of development-stage products if they reach commercialization.
As part of the arrangement, Celularity will retain exclusive manufacturing rights for the licensed products at its FDA-compliant facility in Florham Park, New Jersey. This structure is expected to provide the company with ongoing manufacturing revenue while maintaining economic participation in the portfolio.
“This partnership represents a disciplined step forward in strengthening our capital position while sharpening our focus on longevity medicine,” said Robert J. Hariri, Chairman and Chief Executive Officer.
The transaction also includes an operational restructuring. Employees currently involved in the commercial and product development activities tied to the biomaterials business will transition to the commercial partner upon closing. Celularity said it also plans further workforce reductions as it seeks to lower operating expenses and align resources with its long-term strategy.
Following the agreement, the company intends to concentrate its efforts on developing placental-derived cell therapies targeting biological processes associated with aging, including cellular senescence, chronic inflammation and tissue degeneration. Celularity also plans to explore opportunities in jurisdictions that allow investigational use of cellular therapies under state-level regulatory frameworks.
pH Partners, LLC served as financial advisor to Celularity on the transaction. The company focuses on regenerative and cellular medicine, developing therapeutic products derived from postpartum placenta.